GUCY2C: a Novel Target in Tumor Immunotherapy, Specially in Colorectal Cancer CAR T Therapy!
GUCY2C: a Novel Target in Tumor Immunotherapy, Specially in Colorectal Cancer CAR T Therapy!On April 19, 2022, Innovative Cellular Therapeutics (ICT) company from Shanghai, China receives FDA Fast Track Designation for GCC19CART. GCC19CART is a CAR-T cell therapy based on ICT's unique CoupledCAR® technology...
Detailed information

ROR1, an Emerging Target for Tumor Immunotherapy
ROR1, an Emerging Target for Tumor ImmunotherapyIn 2020, the ROR1 target is favored by pharmaceutical giants such as Merck & Co., CStone Pharmaceuticals, etc. On October 29, 2020, Cstone Pharmaceuticals announced that it has reached a licensing agreement with Lego...
Detailed information

TFPI: a Natural Anticoagulant Protein, Future Therapies for Hemophilia
TFPI: a Natural Anticoagulant Protein, Future Therapies for HemophiliaEvery year, April 17 is observed as World Hemophilia Day. 17th April 2022 marks the observance of the 34rd World Hemophilia Day. Hemophilia is a general term for a group of rare bleeding disorders caused by an inherited ...
Detailed information

TTR: an Important Protein of Amyloidosis, Novel Therapies are Upcoming for Rare Diseases ATTR-CM and ATTR-PN!
TTR: an Important Protein of Amyloidosis, Novel Therapies are Upcoming for Rare Diseases ATTR-CM and ATTR-PN!AstraZeneca and Neurimmune Therapeutics have signed an agreement on Mar. 1, 2022, contributing about $700 million cooperation on NI006 clinical research. NI006 is a transthyretin (TTR) targeting modulator for rare diseas...
Detailed information

DT3C, a Powerful Tool for ADC Drug Internalization In Vitro
DT3C, a Powerful Tool for ADC Drug Internalization In VitroHighlight 1. Can simulate ADC drug function in vitro. 2. Simple preparation of mAb–DT3C complexes. 3. Can combine with mAbs from multiple sources. 4. Antibody internaliza...
Detailed information

ANGPT2 (Ang-2): the First Bispecific Antibody for Eye Vision Loss Therapy, a Novel Target for Tumor Angiogenesis!
ANGPT2 (Ang-2): the First Bispecific Antibody for Eye Vision Loss Therapy, a Novel Target for Tumor Angiogenesis!On January 28, 2022, the FDA approved the first bispecific antibody Vabysmo (Ang-2 x VEGF-A) for eye, to treat two leading causes of vision loss--wet age-related macular degeneration (AMD) and diabetic macular edema (DME...
Detailed information

GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to Fight Multiple Myeloma (MM)
GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to Fight Multiple Myeloma (MM)The first GPRC5D CAR-T study from China (Identifier: NCT05219721), updated on ClinicalTrials.gov website (Feb. 2, 2022), has become a hot topic these days. The Phase I Trial of GPRC5D CAR-T started in Feb. 8, 2022, has b...
Detailed information

CXCR4: An Attractive Target of GPCR family Brings Promising New Drugs for Cancer Therapy!
CXCR4: An Attractive Target of GPCR family Brings Promising New Drugs for Cancer Therapy!BioLineRx Ltd presently has completed a successful pre-New Drug Application (NDA) meeting regarding a chemokine receptor CXCR4 antagonist (Motixafortide), from a report on January 18, 2022. In particular, the biopharmace...
Detailed information

The Collection of Progress of Anti-GPCR Antibody Drugs
The Collection of Progress of Anti-GPCR Antibody DrugsAs mentioned in the article entitled "G protein-Coupled Receptor - Targets for Drug Therapy", GPCRs is an important drug target, and currently about 40% of the marketed drugs are designed based on GPCRs. About 34% of dru...
Detailed information

Chemokine Receptor CCR4: the Key Role of CCR4+Treg Cells in Cancer Immunotherapy
Chemokine Receptor CCR4: the Key Role of CCR4+Treg Cells in Cancer ImmunotherapyOn Jan 17, 2022, Nature Reviews Clinical Oncology (IF: 66.675) published a review entitled "Harnessing cytokines and chemokines for cancer therapy" [1]. In this article, the authors conclude the high potential of targeti...
Detailed information

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalizationX